Dr. Luc Jasmin MD, PhD
Attending Neurosurgeon and a Research Scientist, Cedars-Sinai Medical Center
Member of the Healthcare Council
Council Member Biography
Luc Jasmin, MD, PhD, is an Attending Neurosurgeon and Research Scientist at Cedars Sinai Medical Center in Los Angeles. Dr. Jasmin is involved in a surgical practice and research centered on the treatment of pain and spinal disorders. His clinical work includes cancer spinal surgery as well as treating various pain disorders pharmacologically and surgically such as failed back syndrome, neuropathic pain, cancer pain, and central pain. Dr. Jasmin uses stimulation of the brain and spinal cord as well as the intrathecal pumps to administer various cocktails of drugs. He prescribes a variety of drugs for pain from opiates to anticonvulsants and antidepressants. Dr. Jasmin has also conducted basic research on pain mechanisms and gene therapy for pain. He is a member of several professional societies including American Association of Neurological Surgeons, Royal College of Surgeons, International Association for the Study of Pain, and American Pain Society. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- Attending Neurosurgeon and a Research Scientist, Cedars-Sinai Medical Center
- 2005 - 2006
- Associate Professor of Neurosurgery, UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
- 2000 - Unspecified
- Assistant Professor of Anatomy, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
GLG NewsSM Analyses by Luc Jasmin
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Brain stimulation for high blood pressure?
February 6, 2011
Deep brain stimulation relieves refractory hypertension | www.neurology.org
In the past few years there has been a few reports of an anti-hypertensive effect of deep brain stimulation with Medtronic quadripolar electrodes in patients treated for pain syndromes. Interestingly the antihypertensive effect appears independant of the analgesic effect. The blood pressure is normalized and all anti-hypertensive medications stopped. The reduction of blood pressure appears at the time of the surgery and is still present 27 months later. up.
-
Duloxetine is not for all pains
December 27, 2010
Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial. | www.ncbi.nlm.nih.gov
When faced with a patient with central pain we use drugs approved for peripheral neuropathy. Some class I evidence support the use of gabapentin, pregabalin, lamotrigine, and tramadol for central pain. Hence, Vranken and his colleagues tested the analgesic effect on central pain of the mix noradrenergic-serotoninergic antidepressant duloxetine (Cymbalta). Unfortunately, their study confirms previous data showing that a mix noradrenergic-serotoninergic antidepressant is not an effective analgesic for central pain.
-
The first trial of mini spinal cord stimulators in early 2011
December 15, 2010
New miniature smart chip implant to combat chronic pain | www.physorg.com
After much talk in the past years, a new generation of neurostimulators will be tested in 2011 in Australia. Because of miniaturisation, electrodes and the Implantable Pulse Generator (IPG) are now a single unit that can be directly implanted over the spinal cord or a peripheral nerve. Now that's would be a prime example of minimally invasive surgery.
-
Botox gets the green light for migraine, but does it work?
November 17, 2010
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial | cep.sagepub.com
Chronic migraine is a subtype of migraine, which is defined by 15 or more headaches days per month with 8 or more migraine days for at least 3 months. For the PREEMT2 recruited in 66 sites. 347 patient received Botox and 358 received placebo. The double blind phase lasted 24 weeks, which was followed by an open-label period of 32 weeks. Botox was injected every 12 weeks. The primary endpoint was the incidence of headache day, was significantly lower in the Botox and placebo group.
-
Spinal cord stimulation (SCS) for Parkinson’s disease? We're not there yet.
November 8, 2010
Spinal cord stimulation failed to relieve akinesia or restore locomotion in Parkinson’s disease | www.ncbi.nlm.nih.gov
Spinal cord stimulation (SCS) in dopamine-depleted mice and rats reverses the akinesia and improves locomotion (see Fuentes et al, Science 2009). Because SCS is much less invasive than deep brain stimulation, it is worth testing in Parkinson’s patients. Thevathasan and colleagues (2010) tested SCS in two patients with Parkinson’s disease. There findings show no evidence that SCS improves the motor symptoms of Parkinson’s disease.
GLG Study Groups with Luc Jasmin(?)
| Study Group Name | No. Members |
|---|---|
| Physicians who Prescribe Opioids | 680 |
| Neurologists who Treat Epilepsy (US) | 385 |
| Physicians who Perform Spine Surgery (US) | 274 |
| Opana ER Prescribers (US) | 179 |
| Physicians who Treat Neuropathy (US) | 141 |
GLG Live Meetings with Luc Jasmin(?)
Luc Jasmin has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.